Connecting, Pitching, and Exploring: INOLYSIS at Web Summit 2025 Inolysis attended Web Summit 2025, one of the world’s largest technology and startup conferences, which brings together innovators, investors, and industry leaders from across the globe. This year’s Web Summit was an unmatched, high-energy experience, bringing together thousands of attendees, top-tier CEOs, investors, and innovators from over 150 countries in what truly felt like a global marketplace for startu

INOLYSIS Wins the “Rising Star” Award at Startup Greece Week 2025! INOLYSIS participated in Startup Greece Week 2025 , organized by the Athens Chamber of Commerce and Industry (ACCI) and the Athens Startup Incubator (THEA). The event, held on October 16th, 2025, brought together startups, investors, and industry leaders for a series of workshops and pitching sessions fostering innovation and entrepreneurship. Three investment funds selected INOLYSIS to deliver dedicated pitch

INOLYSIS Engages with Biotech Leaders at Bio3 Startup Pitching We are excited to share that INOLYSIS participated in Session 21a – Startup Pitching at Bio3: BioInnovation Greece, held at Innovathens on September 9th. This session brought together pioneering startups, biotech leaders, and healthtech innovators from Greece and abroad to present their cutting-edge solutions. Our Chief Medicinal Chemist, Alexios Matralis, represented INOLYSIS, showcasing our commitment to advanci

INOLYSIS Receives ERC PoC Funding to Advance Innovative IBD Therapy INOLYSIS has been awarded an ERC Proof of Concept Grant to support the development of a novel oral therapy targeting fibroblast-driven inflammation and fibrosis in IBD . This prestigious grant from the European Research Council (ERC) will accelerate the development of INOLYSIS’s lead compound VM-313, an innovative oral therapy that uniquely targets fibroblasts—the key cellular drivers of inflammation and fib